1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Gastroparesis - Pipeline Review, H1 2015

Gastroparesis - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 37 pages

Gastroparesis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Gastroparesis - Pipeline Review, H1 2015’, provides an overview of the Gastroparesis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroparesis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastroparesis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastroparesis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastroparesis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastroparesis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Gastroparesis - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Gastroparesis Overview 6
Therapeutics Development 7
Pipeline Products for Gastroparesis - Overview 7
Pipeline Products for Gastroparesis - Comparative Analysis 8
Gastroparesis - Therapeutics under Development by Companies 9
Gastroparesis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Gastroparesis - Products under Development by Companies 13
Gastroparesis - Companies Involved in Therapeutics Development 14
GlaxoSmithKline plc 14
RaQualia Pharma Inc. 15
Gastroparesis - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 22
Drug Profiles 23
camicinal - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
ETX-101 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
NG-101 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
RQ-00000010 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
RQ-00201894 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
velusetrag - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Gastroparesis - Recent Pipeline Updates 30
Gastroparesis - Dormant Projects 33
Gastroparesis - Product Development Milestones 34
Featured News and Press Releases 34
Jan 07, 2014: RaQualia Receives a Patent Allowance for Motilin Receptor Agonist in the USA 34
Jan 08, 2013: Theravance And Alfa Wassermann Announce Initiation Of Phase II Study With Velusetrag For Gastroparesis 34
Sep 14, 2012: RaQualia Pharma's Motilin Receptor Agonist RQ-00201894 Advances To Pre-clinical Stage 34
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

List of Tables

Number of Products under Development for Gastroparesis, H1 2015 7
Number of Products under Development for Gastroparesis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Gastroparesis - Pipeline by GlaxoSmithKline plc, H1 2015 14
Gastroparesis - Pipeline by RaQualia Pharma Inc., H1 2015 15
Assessment by Monotherapy Products, H1 2015 16
Number of Products by Stage and Target, H1 2015 18
Number of Products by Stage and Mechanism of Action, H1 2015 20
Number of Products by Stage and Route of Administration, H1 2015 21
Number of Products by Stage and Molecule Type, H1 2015 22
Gastroparesis Therapeutics - Recent Pipeline Updates, H1 2015 30
Gastroparesis - Dormant Projects, H1 2015 33

List of Figures

Number of Products under Development for Gastroparesis, H1 2015 7
Number of Products under Development for Gastroparesis - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 16
Number of Products by Top 10 Targets, H1 2015 17
Number of Products by Stage and Top 10 Targets, H1 2015 18
Number of Products by Top 10 Mechanism of Actions, H1 2015 19
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 21
Number of Products by Stage and Top 10 Molecule Types, H1 2015 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Tanzania

  • December 2016
    9 pages
  • Anti-Infective  

  • Tanzania  

    Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Related Market Segments :

Therapy

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.